Letter

Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation

Emanuele Amata,*,[||] Maria Dichiara,[||] Davide Gentile, Agostino Marrazzo, Rita Turnaturi, Emanuela Arena, Alfonsina La Mantia, Barbara Rita Tomasello, Rosaria Acquaviva, Claudia Di Giacomo, Antonio Rescifina, and Orazio Prezzavento*

Cite This: https://dx.doi.org/10.1021/acsmedchemlett.9b00661

Read Online

ACCESS | Metrics & More | Article Recommendations | SI Supporting Information

ABSTRACT: We report the development of molecular hybrids in which a nitrate group serving as nitric oxide (NO) donor is covalently joined to σ receptor ligands to give candidates for double-targeted cancer therapy. The compounds have been evaluated in radioligand binding assay at both σ receptors and selected compounds tested for NO release. Compounds **9**, **15**, **18**, **19**, and **21** were subjected to MTT test. Compound **15** produced a significant reduction of MCF-7 and Caco-2 cellular viability with comparable IC_{50} as doxorubicin, being also not toxic for fibroblast HFF-1 cells. Compound **15** has shown a σ_1 receptor antagonist/σ_2 receptor agonist profile. Two derivatives of compound **15** lacking the nitrate group did not induce a reduction of MCF-7 cellular viability, suggesting a potential synergistic effect between the σ receptors and the NO-mediated events. Overall, the combination of NO donor and σ receptors ligands provided compounds with beneficial effects for the treatment of cancer.

KEYWORDS: Sigma receptors, nitric oxide, nitric oxide donors, cancer, bifunctional ligands

Cpd	X	Y	n	m	Substitution
9–16	N	CH	2–5	0	meta; para
17–20	CH	N	0	0, 1	meta; para

Sigma (σ) receptors represent a unique receptor class involved in various biological and pathological conditions.[1] Two σ receptors subtypes are recognized and termed sigma-1 (σ_1) and sigma-2 (σ_2), having different structures and biological functions.[2,3] The σ_1 receptor is a 25.3 kDa polypeptide that has been cloned in several species and recently crystallized revealing a trimeric architecture.[4,5] The σ_1 receptor has been identified as a ligand-operated chaperone protein localized in the mitochondria-associated endoplasmic reticulum (ER) membranes (MAM). At the MAM, the σ_1 receptor forms a complex with another chaperone, the immunoglobulin heavy-chain binding protein (BiP). The σ_1 receptor-BiP complex is silent and only activated when cells are stimulated by σ_1 receptor agonists like (+)-pentazocine [(+)-PTZ] or undergo prolonged stress.[6] In contrast, haloperidol, methamphetamine, and NE-100 can preserve the σ_1 receptor-BiP complex in a silent state.[7]

The σ_2 receptor is a poorly understood protein whose identification has been controversial. In 2017, Alon and co-workers identified the σ_2 receptor as an endoplasmic reticulum-resident transmembrane protein (TMEM97) playing a role in the cholesterol homeostasis and the sterol transporter Niemann−Pick disease type C1.[8] Despite the challenges in identifying its true identity, σ_2 receptor and its ligands, as determined in radioligand binding assay using [^{3}H]DTG,[9,10] have earned a growing scientific interest due to its involvement

in several pathological states.[11,12] The overexpression of the σ_2 receptor has been found in several cancer cells and proliferating tumors such as lung, colorectal, and breast.[13] Due to a 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, the σ_2 receptor also represents a significant clinical biomarker for determining the proliferative status of solid tumors.[14,15] A vast number of data support the use of σ_1 receptor antagonists and σ_2 receptor agonists for the treatment of cancer due to their antiproliferative effects.[16−20] Rimcazole and haloperidol, as well as other σ receptors ligands endowed with opportune functional profile, have been shown to inhibit cell proliferation of several cancer cell lines.[21,22]

Nitric oxide (NO) is a short-lived gas with a dichotomous role in tumor biology. NO operates as a tumor progressor or suppressor based on its concentration, duration of exposure, and cell sensitivity.[23] For instance, μM concentrations of NO result in antitumor effects, while pM−nM concentrations promote cytoprotective effects. In this view, the modulation of

Scheme 1. Synthetic Strategy for the Preparation of Target Compounds[a]

[a]Reagents and conditions: (i) 4-benzylpiperidine, Br[(CH$_2$)$_{1-4}$]CN, NaI, K$_2$CO$_3$, DMF, 60 °C, overnight; (ii) LiAlH$_4$, THF, rt, N$_2$; (iii) AgNO$_3$, CH$_3$CN, rt; (iv) EDC, HOBT, CH$_3$CN, rt, 5 h.

Table 1. σ_1 and σ_2 Binding Assays for Compounds 9−20

compd	X	Y	n	m	substitution	$K_i \pm SD^a$ (nM) σ_1	σ_2
9	N	CH	2	0	meta	49 ± 1	330 ± 9
10	N	CH	3	0	meta	64 ± 0.7	93 ± 3
11	N	CH	4	0	meta	148 ± 1	75 ± 2
12	N	CH	5	0	meta	50 ± 0.9	142 ± 13
13	N	CH	2	0	para	89 ± 2	2673 ± 44
14	N	CH	3	0	para	145 ± 12	230 ± 18
15	N	CH	4	0	para	250 ± 9	89 ± 2
16	N	CH	5	0	para	93 ± 2	70 ± 3
17	CH	N	0	0	meta	24 ± 0.6	19 ± 0.2
18	CH	N	0	1	meta	19 ± 1	320 ± 4
19	CH	N	0	0	para	22 ± 0.8	270 ± 5
20	CH	N	0	1	para	170 ± 6	2514 ± 24
haloperidol						2.5 ± 0.4	16 ± 2
(+)-PTZ						4.7 ± 0.7	1465 ± 224
DTG						ND^b	18 ± 1

[a]Each value is the mean ± SD of at least two experiments performed in triplicate. [b]Not determined.

NO levels seems to have benefits in the treatment of cancer. However, NO is a reactive and unstable gas; thus, the use of NO donors (NODs) is preferred since these agents are stable chemical compounds able to release NO under specific chemical or enzymatical conditions. In order to ensure a high and effective release of cytotoxic amounts of NO, the choice of the releasing agent is crucial. Among the different classes of donors, organic nitrates have been reported to release adequate amounts of NO.[16,24]

The cytotoxic activity may be carried out by NODs alone, or they may be conjugated or embedded in chemical compounds that possess additional antitumoral action for double-targeted cytotoxic activity.[25,26] On the basis of the aforementioned, the purpose of the present work is the development, biological evaluation, and molecular modeling studies of a series of molecular hybrids where the cytotoxic activity of the NOD is conjugated with that of σ receptors for optimal effect.[27]

Compounds 9−20 were synthesized according to the steps illustrated in Scheme 1. Starting from commercially available 4-benzylpiperidine, intermediates 1−4 were obtained with opportune nitrile compounds and then converted into the corresponding amine derivatives by reaction with LiAlH$_4$.[6,16] The amine intermediates underwent condensation with [(nitrooxy)methyl]benzoic acid (5, 6) or para- or meta-[(nitrooxy)methyl]phenylacetic acid (7, 8) previously prepared via nitration with AgNO$_3$ to give the final compounds 9−16. Compounds 17−20 were obtained through condensation of 1-benzylpiperidin-4-amine with the same acids 5−8.

The synthesized compounds were evaluated for affinity at both σ_1 and σ_2 receptors through radioligand binding assay (Table 1). Within the series bearing a 4-benzylpiperidine (9−16), the meta-substituted compound 9 has shown a preferential σ_1 receptor affinity with K_i value of 49 nM, and 330 nM for the σ_2 receptor. The elongation to three-carbon chain (10)

Figure 1. (a) 3D superposition of the best-docked pose for **9** (orange) and **11** (green) bound to the σ_1 receptor orthosteric site. The different lengths of the aliphatic linker reverse the orientation of the ligand inside the receptor. (b) Top-scored docking poses for **9** (orange) and **13** (magenta) bound to the σ_1 receptor orthosteric site. The different position of the nitrate group allows better interaction with His154 (green dotted line).

increased the σ_2 receptor affinity by more than 3-fold with $K_i\sigma_1$ value of 64 nM and $K_i\sigma_2$ of 93 nM. The increased σ_2 receptor affinity has also been maintained in compound **11** with a K_i value of 75 nM, although in the four-carbon chain, the σ_1 receptor affinity (148 nM) is reduced. Further elongation of the chain to five carbons takes back σ_1 receptor preferential affinity with a K_i value of 50 nM over the σ_2 receptor (K_i value of 142 nM).

At the same time, the *para* substitution of the nitrate group gives compounds with generally lower affinity with respect to both receptor subtypes. It is observed an improvement of the σ_2 receptor affinity with the linker elongation. Indeed, compound **13** has a $K_i\sigma_2$ of 2673 nM, while compound **16** has a $K_i\sigma_2$ of 70 nM. In terms of σ_1 receptor affinity, compounds **9–16** show a mixed behavior with affinity ranging from 89 nM for compound **13** to 249 nM for compound **15**. Compounds bearing the 1-benzylpiperidin-4-amine (**17–20**) have shown worthy σ_1 receptor affinities and a general lower affinity at the σ_2 receptor. In particular, compounds **17–19** have a σ_1 receptor affinity in the low double digits nM range ($K_i\sigma_1$ of 24, 19, and 22 nM, respectively), while only compound **17** shows σ_2 receptor affinity in the same range ($K_i\sigma_2$ of 19 nM). The other compounds show a lower affinity to the σ_2 receptor, which leads to a >10 times selectivity with respect to the σ_1 receptor.

A docking study was conducted to identify and evaluate the key molecular interactions involved in the receptor/ligand recognition. The crystal structure of the σ_1 receptor PD144418 (PDB code 5HK1)[4] reveals an occluded and elongated binding cavity in a similar β-barrel fashion, with the highly conserved Glu172 amino acid residue located near the center of the cavity, forming a salt bridge with the ligands. Since all compounds possess a tertiary amine, we performed the study considering the *N*-protonated structures (pH = 7.4). Therefore, the formation of the salt bridge was used as a filter for the docking poses. The calculated free binding energies (ΔG) and K_i values to the catalytic site of the σ_1 receptor for compounds **9–20** and haloperidol are reported in Table S1.

Active analysis of the site showed that the orientation changes according to the length of the ligands and the protonated *N*-position. Moreover, the position of the

protonated piperidine ring is rather characteristic, being close to the carboxyl function of Glu172. The docking studies conducted upon the σ_2 receptor were performed by using its homology model previously built by us.[28] In this case, the salt bridge interactions between the ligands and the residues Asp29 and Asp56 were considered. In the 4-benzylpiperidine series with the nitrate group in the *meta* position (**9–12**), compound **9** showed a preferential affinity for the σ_1 receptor with a K_i value of 49 nM.

Compound **9** is placed inside the receptor site with the piperidinium proton engaged in a salt bridge interaction with Glu172 and a hydrogen bond with N–H amide. The nitrate group is positioned on the opposite side helices $\alpha4$ and $\alpha5$, showing polar interactions with the residues Asp126 and His154. The optimal position of the piperidine ring favors the $\pi-\pi$ stacking of the hydrogen in position 4 of the piperidine system with the residue Tyr103. The benzyl group is involved in hydrophobic interactions with the Leu182 and Met93 residues. The elongation to the four-carbon chain (**11**) decreases the affinity for the σ_1 receptor while increasing the affinity for the σ_2 receptor. Indeed, derivative **11** has an inverted orientation with respect to derivative **9**, with the nitrate group toward the helix $\alpha5$ to allow the accommodation of the aliphatic chain within the receptor pocket (Figure 1a).

The *para* substitution of the nitrate group (**13–16**) decreases the affinity with respect to the ligands substituted in the *meta* position. This is probably due to a lower cation−π interaction with the His154 residue (Figure 1b). An elongation of the aliphatic portion of the ligands leads to a better affinity for the σ_2 receptor. The most similar compounds in the series (**11** and **16**) show comparable interactions within the σ_2 receptor pocket. Both form the salt bridge with the residue Asp56 while the benzyl portion in position 4 to the piperidine ring shows aliphatic interactions with the residues Leu70, Met108, Pro113, and Val146. The nitrate group establishes electrostatic interactions with the Arg36 residue, discriminating against the different affinity between the different isomers. A detailed description of the interactions with σ_2 receptor is reported in the Molecular Docking section in the Supporting Information.

Compound **18** showed the preeminent affinity to the σ_1 receptor. On this compound, a molecular dynamics (MD) simulation was performed (Supporting Information). An elongation of the aliphatic portion of the ligands leads to a better affinity for σ_2 receptor.

Once the affinity profiles of the synthesized compounds at σ receptors were evaluated, we determined the ability of these compounds to release NO. Nitrite content was measured by the Griess method incubating the compounds (100 μM), at 37 °C, in Tris-HCl buffer for 30 min (Figure 2).


Figure 2. Total nitrite content measured using Griess reagent.

For this assay, we selected the compounds based on their affinity profile against σ receptors. In particular, we evaluated compounds **9**, **11**, **15**, and **17–19**, having shown good affinity at both receptors or prevalence for one receptor subtype. Compounds **9** and **15** were able to release a significant amount of NO in the μM range (**9**, 13.0 ± 0.5 μM; **15**, 13.0 ± 0.4 μM). The amount of NO released by compound **18** was 1.3 ± 0.2 μM, while compound **19** produced 6.3 ± 0.3 μM NO. Negligible NO amounts were detected for compounds **11** and **17** (data not shown).

After having obtained the desired chemical tools, we evaluated their activity in the appropriate cell lines. We evaluated those compounds that, in previous experiments, have been demonstrated to possess the desired profile (compounds **9**, **15**, **18**, and **19**). Two cancer cell lines were selected, Caco-2 and MCF-7 cells, for their expression of both σ receptors. Although MCF-7 cells are reported to exclusively express the σ_2 subtypes, a Western blot analysis has shown the presence of the σ_1 isoform in our in-house cell line (Figure S4).[29] The toxicity against human fibroblast HFF-1 cells was also evaluated. Doxorubicin (**21**) was used as the standard cytotoxic compound. Results showed a reduction of cellular viability on both Caco-2 and MCF-7 cell lines for compounds **9** and **15** (Table 2). These compounds were those with a higher rate of NO release. Measured IC_{50} values were better with respect to compound **21** for MCF-7 cells, with IC_{50} of 36

Table 2. MTT Test on MCF-7, Caco-2, and HFF-1 for Compounds 21, 9, 15, 18, and 19

compd	$IC_{50} \pm SD\ (\mu M)^a$		
	MCF-7	Caco-2	HFF-1
21	44 ± 0.3	21 ± 0.3	>100[b]
9	36 ± 0.2	59 ± 0.5	>100[b]
15	26 ± 0.4	28 ± 0.2	>100[b]
18	>100[b]	>100[b]	>100[b]
19	>100[b]	>100[b]	>100[b]

[a]Each value is the mean ± SD of at least two experiments performed in quadruplicate. [b]Cell viability reduction lower than 50% at 100 μM.

μM for compound **9** and 26 μM for compound **15**. None of the synthesized compounds, nor compound **21**, were demonstrated to be toxic for the human fibroblasts HFF-1 at the maximal tested concentration. Compounds **18** and **19** have been shown to be nontoxic for the three evaluated cell lines (IC_{50} > 100 μM), probably due to the lower rate of NO release and to an unsuitable functional profile at σ receptors.

In order to determinate the precise mechanism for the reduction of cellular viability, compound **15** (IC_{50} concentration) was evaluated in combination with the σ_1 receptor agonist (+)-PTZ (1 μM) and the σ_2 receptor antagonist 1-phenethylpiperidine (AC927, 1 μM) by MTT.[30]

Incubation of compound **15** with (+)-PTZ or AC927 wholly restored the loss of cell viability induced by **15** alone (Figure 3). This outlines a σ_1 and σ_2 receptors involvement in the observed cellular events and a σ_1 receptor antagonist/σ_2 receptor agonist functional profile for compound **15**.


Figure 3. Effects of compound **15** in combination with the selective σ_1 receptor agonist (+)-PTZ and σ_2 receptor antagonist AC927 on MCF-7 and Caco-2 viability by MTT test.

To dig into the dual mechanism of the prepared compounds, we tested fragments **5** and **22a,b** and synthesized two derivatives of compound **15** lacking the nitrate function, compounds **23a** and **23b**, as negative control (Table 3 and Scheme S1).[31,32]

The fragments **5** and **22a,b** have shown no significant viability reduction on MCF-7 and no affinity for both σ receptors. Compound **23a** showed a loss of affinity at both σ receptors, while compound **23b** retained a similar affinity profile at both σ receptors with respect to compound **9** or **15**. When evaluated on the MCF-7 cell line, compound **23a** induced lower than 50% viability reduction at 100 μM, while compound **23b** had an IC_{50} of 87 μM. Overall compound **23b**, while maintaining a similar profile against σ receptors, showed a lower ability in reducing MCF-7 viability, thus sustaining a possible synergistic effect between σ receptors and the NO-mediated events.

In conclusion, this contribution reports the development of novel hybrid compounds able to release NO and to bind σ receptors as candidates for double-targeted cancer therapy. The compounds have been evaluated for their affinity at σ receptors and ability to release NO. Four compounds showed the desired profile with compounds **9** and **15** also able to induce a marked loss of viability in MCF-7 and Caco-2 cell lines while not being toxic for healthy human fibroblast HFF-1.

Table 3. Binding Assays and MTT Viability Test on MCF-7 for Compounds 22a,b, 23a,b, and 5

5, R = CH$_2$ONO$_2$
22a, R = CH$_2$OH
22b, R = CH$_3$

23a, R = CH$_2$OH
23b, R = CH$_3$

compd	$K_i \pm SD^a$ (nM)		IC$_{50} \pm$ SD (μM)^b
	σ_1	σ_2	MCF-7
5	>10000^c	>10000^c	>100^d
22a	>10000^c	>10000^c	>100^d
22b	>10000^c	>10000^c	>100^d
23a	711 ± 127	2600 ± 730	>100^d
23b	62 ± 3	127 ± 16	87 ± 0.3

^{a}Each value is the mean ± SD of at least two experiments performed in triplicate. ^{b}Each value is the mean ± SD of at least two experiments performed in quadruplicate. ^{c}Radioligand displacement lower than 50% at 10 μM. ^{d}Cell viability reduction lower than 50% at 100 μM.

In cellular experiments involving the use of selective σ receptors agonist and antagonist, compound **15** has shown a σ_1 receptor antagonist/σ_2 receptor agonist functional profile. The elimination of the nitrate function of compound **15** as in compounds **23a,b** determined the loss of its ability to reduce MCF-7 viability sustaining a possible synergistic effect between the σ receptors and the NO-mediated events. Molecular docking studies have shown that the length of the aliphatic linker has an essential role in the orientation of the ligands inside the receptor pocket and for σ_1/σ_2 selectivity. The nitrate group stabilizes the ligand/receptor complex to cation−π interaction with His154 residue in the σ_1 receptor, also confirmed by the MD simulation, and with Phe71 and Pro113 residues in the σ_2 receptor. Overall, the combination of NO donor and σ receptors ligands provided compounds with potential beneficial effects in the treatment of neoplastic disorders.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00661.

General synthetic methods and spectral data of final compounds, procedures for in vitro biological assays, and computational methods (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Emanuele Amata − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy;* ⓞ orcid.org/0000-0002-4750-3479; Phone: (+39) 0957384102; Email: eamata@unict.it

Orazio Prezzavento − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy;* ⓞ orcid.org/0000-0002-3521-264X; Phone: (+39) 3396392909; Email: prezzave@unict.it

Authors

Maria Dichiara − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy*

Davide Gentile − *Department of Drug Sciences, Chemistry Section, University of Catania, 95125 Catania, Italy*

Agostino Marrazzo − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy;* ⓞ orcid.org/0000-0002-8728-8857

Rita Turnaturi − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy;* ⓞ orcid.org/0000-0002-5895-7820

Emanuela Arena − *Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, 95125 Catania, Italy*

Alfonsina La Mantia − *Department of Drug Sciences, Biochemistry Section, University of Catania, 95125 Catania, Italy*

Barbara Rita Tomasello − *Department of Drug Sciences, Biochemistry Section, University of Catania, 95125 Catania, Italy*

Rosaria Acquaviva − *Department of Drug Sciences, Biochemistry Section, University of Catania, 95125 Catania, Italy*

Claudia Di Giacomo − *Department of Drug Sciences, Biochemistry Section, University of Catania, 95125 Catania, Italy*

Antonio Rescifina − *Department of Drug Sciences, Chemistry Section, University of Catania, 95125 Catania, Italy;* ⓞ orcid.org/0000-0001-5039-2151

Complete contact information is available at:
https://pubs.acs.org/10.1021/acsmedchemlett.9b00661

■ ABBREVIATIONS

σ, sigma; σ_1, sigma-1; σ_2, sigma-2; ER, endoplasmic reticulum; [^{3}H]-DTG, [^{3}H]-1,3 di-*o*-tolylguanidine; NO, nitric oxide; NOD, nitric oxide donor; AC927, 1-phenetylpiperidine

■ REFERENCES

(1) Kim, F. J. Introduction to Sigma Proteins: Evolution of the Concept of Sigma Receptors. *Handb. Exp. Pharmacol.* **2017**, 244, 1−11.

(2) Schmidt, H. R.; Kruse, A. C. The Molecular Function of sigma Receptors: Past, Present, and Future. *Trends Pharmacol. Sci.* **2019**, 40, 636−654.

(3) Weber, F.; Wunsch, B. Medicinal Chemistry of sigma1 Receptor Ligands: Pharmacophore Models, Synthesis, Structure Affinity Relationships, and Pharmacological Applications. *Handb. Exp. Pharmacol.* **2017**, 244, 51−79.

(4) Schmidt, H. R.; Zheng, S.; Gurpinar, E.; Koehl, A.; Manglik, A.; Kruse, A. C. Crystal structure of the human sigma1 receptor. *Nature* **2016**, 532, 527−530.

(5) Kim, F. J.; Pasternak, G. W. sigma1 Receptor ligand binding: an open-and-shut case. *Nat. Struct. Mol. Biol.* **2018**, *25*, 992−993.

(6) Hayashi, T.; Su, T. P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell* **2007**, *131*, 596−610.

(7) Morales-Lazaro, S. L.; Gonzalez-Ramirez, R.; Rosenbaum, T. Molecular Interplay Between the Sigma-1 Receptor, Steroids, and Ion Channels. *Front. Pharmacol.* **2019**, *10*, 419.

(8) Alon, A.; Schmidt, H. R; Wood, M. D.; Sahn, J. J.; Martin, S. F.; Kruse, A. C. Identification of the gene that codes for the sigma2 receptor. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114*, 7160−7165.

(9) Nastasi, G.; Miceli, C.; Pittala, V.; Modica, M. N.; Prezzavento, O.; Romeo, G.; Rescifina, A.; Marrazzo, A.; Amata, E. S2RSLDB: a comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands. *J. Cheminf.* **2017**, *9*, 3.

(10) Prezzavento, O.; Arena, E.; Sanchez-Fernandez, C.; Turnaturi, R.; Parenti, C.; Marrazzo, A.; Catalano, R.; Amata, E.; Pasquinucci, L.; Cobos, E. J. (+)-and (−)-Phenazocine enantiomers: Evaluation of their dual opioid agonist/sigma1 antagonist properties and anti-nociceptive effects. *Eur. J. Med. Chem.* **2017**, *125*, 603−610.

(11) Huang, Y. S.; Lu, H. L.; Zhang, L. J.; Wu, Z. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. *Med. Res. Rev.* **2014**, *34*, 532−566.

(12) Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. *Cancer Res.* **2002**, *62*, 313−322.

(13) van Waarde, A.; Rybczynska, A. A.; Ramakrishnan, N. K.; Ishiwata, K.; Elsinga, P. H.; Dierckx, R. A. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. *Biochim. Biophys. Acta, Biomembr.* **2015**, *1848*, 2703−2714.

(14) Zeng, C.; McDonald, E. S.; Mach, R. H. Molecular Probes for Imaging the Sigma-2 Receptor: In Vitro and In Vivo Imaging Studies. *Handb. Exp. Pharmacol.* **2016**, *244*, 309−330.

(15) McDonald, E. S.; Doot, R. K.; Young, A. J.; Schubert, E. K.; Pryma, D. A.; Farwell, M. D.; Tchou, J.; Nayak, A.; Ziober, A.; Feldman, M. D.; DeMichele, A.; Clark, A. S.; Shah, P. D.; Lee, H.; Carlin, S. D.; Mach, R. H.; Mankoff, D. A. Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status. *J. Nucl. Med.* **2019**, DOI: 10.2967/jnumed.119.232363.

(16) Amata, E.; Dichiara, M.; Arena, E.; Pittala, V.; Pistara, V.; Cardile, V.; Graziano, A. C. E.; Fraix, A.; Marrazzo, A.; Sortino, S.; Prezzavento, O. Novel Sigma Receptor Ligand-Nitric Oxide Photo-donors: Molecular Hybrids for Double-Targeted Antiproliferative Effect. *J. Med. Chem.* **2017**, *60*, 9531−9544.

(17) Olivieri, M.; Amata, E.; Vinciguerra, S.; Fiorito, J.; Giurdanella, G.; Drago, F.; Caporarello, N.; Prezzavento, O.; Arena, E.; Salerno, L.; Rescifina, A.; Lupo, G.; Anfuso, C. D.; Marrazzo, A. Antiangiogenic Effect of (+/-)-Haloperidol Metabolite II Valproate Ester (+/-)-MRJF22 in Human Microvascular Retinal Endothelial Cells. *J. Med. Chem.* **2016**, *59*, 9960−9966.

(18) Tesei, A.; Cortesi, M.; Zamagni, A.; Arienti, C.; Pignatta, S.; Zanoni, M.; Paolillo, M.; Curti, D.; Rui, M.; Rossi, D.; Collina, S. Sigma Receptors as Endoplasmic Reticulum Stress "Gatekeepers" and their Modulators as Emerging New Weapons in the Fight Against Cancer. *Front. Pharmacol.* **2018**, *9*, 711.

(19) Floresta, G.; Dichiara, M.; Gentile, D.; Prezzavento, O.; Marrazzo, A.; Rescifina, A.; Amata, E. Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands. *Int. J. Mol. Sci.* **2019**, *20*, 488.

(20) Amata, E.; Rescifina, A.; Prezzavento, O.; Arena, E.; Dichiara, M.; Pittala, V.; Montilla-Garcia, A.; Punzo, F.; Merino, P.; Cobos, E. J.; Marrazzo, A. (+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropa necarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties. *J. Med. Chem.* **2018**, *61*, 372−384.

(21) Happy, M.; Dejoie, J.; Zajac, C. K.; Cortez, B.; Chakraborty, K.; Aderemi, J.; Sauane, M. Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation. *Biochem. Biophys. Res. Commun.* **2015**, *456*, 683−688.

(22) Spruce, B. A.; Campbell, L. A.; McTavish, N.; Cooper, M. A.; Appleyard, M. V.; O'Neill, M.; Howie, J.; Samson, J.; Watt, S.; Murray, K.; McLean, D.; Leslie, N. R.; Safrany, S. T.; Ferguson, M. J.; Peters, J. A.; Prescott, A. R.; Box, G.; Hayes, A.; Nutley, B.; Raynaud, F.; Downes, C. P.; Lambert, J. J.; Thompson, A. M.; Eccles, S. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. *Cancer Res.* **2004**, *64*, 4875−4886.

(23) Sakuma, S.; Ikeda, Y.; Inoue, I.; Yamaguchi, K.; Honkawa, S.; Kohda, T.; Minamino, S.; Fujimoto, Y. Nitric oxide represses the proliferation of Caco-2 cells by inducing S-G2/M cell cycle arrest. *Int. J. Physiol. Pathophysiol. Pharmacol.* **2019**, *11*, 205−211.

(24) Wang, P. G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A. J. Nitric oxide donors: chemical activities and biological applications. *Chem. Rev.* **2002**, *102*, 1091−1134.

(25) Huang, Z.; Fu, J.; Zhang, Y. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. *J. Med. Chem.* **2017**, *60*, 7617−7635.

(26) Ding, Q. G.; Zang, J.; Gao, S.; Gao, Q.; Duan, W.; Li, X.; Xu, W.; Zhang, Y. Nitric oxide donor hybrid compounds as promising anticancer agents. *Drug Discoveries Ther.* **2016**, *10*, 276−284.

(27) Amata, E.; Dichiara, M.; Arena, E.; Pittalà, V.; Pistarà, V.; Cardile, V.; Graziano, A. C. E.; Fraix, A.; Marrazzo, A.; Sortino, S.; Prezzavento, O. Novel sigma receptors ligands-nitric oxide photo-donor: molecular hybrids for double-targeted antiproliferative effect. *J. Med. Chem.* **2017**, *60*, 9531−9544.

(28) Floresta, G.; Amata, E.; Barbaraci, C.; Gentile, D.; Turnaturi, R.; Marrazzo, A.; Rescifina, A. A Structure- and Ligand-Based Virtual Screening of a Database of "Small" Marine Natural Products for the Identification of "Blue" Sigma-2 Receptor Ligands. *Mar. Drugs* **2018**, *16*, 384.

(29) Kim, F. J.; Maher, C. M. Sigma1 Pharmacology in the Context of Cancer. *Handb. Exp. Pharmacol.* **2017**, *244*, 237−308.

(30) Bucolo, C.; Campana, G.; Di Toro, R.; Cacciaguerra, S.; Spampinato, S. Sigma1 recognition sites in rabbit iris-ciliary body: topical sigma1-site agonists lower intraocular pressure. *J. Pharmacol. Exp. Ther.* **1999**, *289*, 1362−1369.

(31) Pisani, L.; Iacobazzi, R. M.; Catto, M.; Rullo, M.; Farina, R.; Denora, N.; Cellamare, S.; Altomare, C. D. Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. *Eur. J. Med. Chem.* **2019**, *161*, 292−309.

(32) Wold, S.; Sjöström, M.; Eriksson, L. PLS-regression: a basic tool of chemometrics. *Chemom. Intell. Lab. Syst.* **2001**, *58*, 109−130.

■ NOTE ADDED AFTER ASAP PUBLICATION

This paper was originally published ASAP on April 15, 2020. Due to a production error, additional corrections were needed to Tables 2 and 3. The corrected version was reposted on April 15, 2020.